Guest column : Implications of the #Januvia patent lawsuit in India

The banning of diabetes drug pioglitazone (now looking set to be revoked) has put Merck’s patented drug sitagliptin or Januvia back into the limelight in India. Critics of the ban have highlighted the added expense of moving patients from pio to sitagliptin, a possible alternative. This is a good time to take another look at …

Advertisement

Cervical cancer vaccine : do your homework

In recent months, I've had three mothers wonder aloud whether they should give their young daughters the cervical cancer shots.  Our discussions brought alive the very real dilemma that the highly-visible launch of these products has triggered among parents. Probably, even more than the usual so-called 'optional' vaccines against pneumonia or chicken pox. The first was a dentist with …